INNOVATIVE APPROACHES IN CARDIOVASCULAR DISEASE
SER100 is an opioid-1 (ORL1, nociceptin receptor) partial agonist previously known as ZP120. SER100 was acquired from Zealand Pharma A/S in 2010. The results from previous studies in chronic and acute heart failure indicate that SER100 has a potential to treat isolated systolic hypertension (ISH), and indication which Serodus is pursuing with a Clinical Phase IIa trial. The Phase IIa trial is completed. For key results, see here.
Patients with ISH are more likely to develop myocardial and vascular remodelling and arteriosclerosis, which predispose them to stroke, renal failure and myocardial infarction. Diabetes, chronic renal failure and obesity are other risk factors in patients with established ISH, and these patients have a significantly higher incidence of congestive heart failure than those with only increased diastolic pressure.
SER150 is a dual acting thromboxane receptor antagonist and thromboxane synthase inhibitor, previously known as EV-077. The product was licensed from the Swiss company Evolva SA in 2013. Early clinical studies indicate an effect on albuminuria in patients with diabetic nephropathy. Serodus is about to start a clinical phase II study in this patient group.
SER150 has also been shown to possess antiviral properties. In mouse models SER150 was effective in the prophylaxis and treatment of ebola and influenza.
SER130 is an interleukin-4 (IL-4) partial receptor agonist, which inhibits liberation of TNFα in cells stimulated in an inflammatory cascade. In experimental inflammatory in vivo models SER130 has proven to inhibit inflammation. SER130 is a "First in Class" compound and will shortly enter the preclinical development phase. Acute Myocardial Infarction commonly known as heart attack, results from interruption of blood supply to a part of the heart muscle, causing the heart cells to die. In the first few hours after a heart attack a pronounced inflammation is mobilized in the heart tissue around the area with significant decrease in blood and oxygen supply. This inflammatory process worsens the tissue damage and appears to play a pivotal role in the scar formation and may also increase the short-term risk of recurrent cardiac ischemia. The larger the scar, the greater is the risk for the patient developing heart failure. Patients with heart failure suffer from a very high mortality rate. SER130 is expected to inhibit this early inflammatory process and thereby reduce the size of scaring developed after a heart attack. For more information, see article in Cytokine.
SER140 is an interleukin-1 (IL-1) receptor antagonist for treatment of Type 2 diabetes, which inhibits liberation of TNFα in cells stimulated in an inflammatory cascade. Numerous reports have demonstrated the involvement of IL-1 in various inflammatory diseases or in diseases where inflammation plays a major role in the development of the disease. In type 2 diabetes inflammatory processes are activated not only around the insulin producing cells in the pancreas, but also around the insulin receptors in the peripheral organs and tissues which are supposed to be responsible for decreased insulin sensitivity during the early phases of diabetes. See article in J. Neuroinflammation 2014.
SER140 is in pharmacological testing by Phlogo ApS, Serodus' Danish subsidiary.